<p>Tevogen Bio Holdings Inc. announced significant scientific and operational milestones achieved in 2025, which were reported during the J.P. Morgan Healthcare Conference. The company advanced its proprietary ExacTcell™ platform, enhancing laboratory yields and supporting improved consistency and scalability for its cytotoxic T lymphocyte (CTL) therapies. Tevogen expanded its CTL pipeline to cover multiple high-value indications, including additional HLA restrictions for its SARS-CoV-2-specific product, Epstein-Barr virus (EBV) associated lymphomas, chronic hepatitis B, and HPV-related cancers. These advancements were supported by Tevogen.AI, the company’s analytics division, to aid in target discovery and prioritization. The updates reflect Tevogen’s progress toward developing a scalable, multi-program cell therapy platform and establishing in-house GMP manufacturing capabilities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623865) on January 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Tevogen Bio Expands T Cell Therapy Pipeline and Boosts Manufacturing Capacity